Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
TELA
$0.8364
$
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Next Earnings
2026-02-25
Beta
0.866
Average Volume
Market Cap
Last Dividend
CIK
0001561921
ISIN
US8723811084
CUSIP
872381108
CEO
Antony Koblish
Sector
Healthcare
Industry
Medical - Devices
Full Time Employees
209
IPO Date
2019-11-08
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 8,550 shares of its common stock to three newly-hired employees, with a grant date of February 18, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. | GlobeNewsWire | 2026-02-20 16:05:00 |
| TELA Bio, Inc. (NASDAQ:TELA) Receives Consensus Recommendation of “Hold” from Analysts | TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) has received an average rating of "Hold" from the five brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average | Defense World | 2026-02-14 03:27:07 |
| TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees, with a grant date of January 20, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. | GlobeNewsWire | 2026-01-23 16:05:00 |
| TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. | GlobeNewsWire | 2025-12-12 16:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 424B3 | 2025-12-23 | 2025-12-23 | View Filing |
| EFFECT | 2025-12-18 | 2025-12-19 | View Filing |
| S-3 | 2025-12-12 | 2025-12-12 | View Filing |
| SC 13G/A | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| 424B5 | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 424B5 | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-03 | 2025-11-03 | View Filing |
| 3 | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| SC 13G/A | 2025-10-15 | 2025-10-15 | View Filing |
| 4 | 2025-10-10 | 2025-10-10 | View Filing |
| 3 | 2025-10-10 | 2025-10-10 | View Filing |
| 8-K | 2025-10-09 | 2025-10-09 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| S-8 | 2025-08-11 | 2025-08-11 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 4 | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-06-02 | 2025-06-02 | View Filing |
| 8-K | 2025-06-02 | 2025-06-02 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 4 | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-30 | 2025-05-30 | View Filing |
| SC 13G/A | 2025-05-30 | 2025-05-30 | View Filing |
| SC 13G | 2025-05-30 | 2025-05-30 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13G/A | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13G/A | 2025-05-07 | 2025-05-07 | View Filing |
| ARS | 2025-04-17 | 2025-04-17 | View Filing |
| DEFA14A | 2025-04-17 | 2025-04-17 | View Filing |
| DEF 14A | 2025-04-17 | 2025-04-17 | View Filing |
| PRE 14A | 2025-04-07 | 2025-04-07 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 4 | 2025-04-02 | 2025-04-02 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| S-8 | 2025-03-21 | 2025-03-21 | View Filing |
| 10-K | 2025-03-21 | 2025-03-21 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-21 | 2025-02-21 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-13 | 2025-02-13 | View Filing |
| SC 13G | 2025-02-12 | 2025-02-12 | View Filing |
| SC 13G/A | 2025-01-31 | 2025-01-31 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| SC 13G | 2024-10-29 | 2024-10-29 | View Filing |
| SC 13G/A | 2024-10-28 | 2024-10-28 | View Filing |
| SC 13D/A | 2024-10-25 | 2024-10-25 | View Filing |
| 4 | 2024-10-24 | 2024-10-24 | View Filing |
| 4 | 2024-10-24 | 2024-10-24 | View Filing |
| 4 | 2024-10-24 | 2024-10-24 | View Filing |
| 4 | 2024-10-24 | 2024-10-24 | View Filing |
| 8-K | 2024-10-23 | 2024-10-23 | View Filing |
| 424B5 | 2024-10-23 | 2024-10-23 | View Filing |
| 424B5 | 2024-10-22 | 2024-10-22 | View Filing |
| 8-K | 2024-10-22 | 2024-10-22 | View Filing |
| SC 13D/A | 2024-10-01 | 2024-10-01 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
| 4 | 2024-08-06 | 2024-08-06 | View Filing |
| SC 13G | 2024-07-30 | 2024-07-30 | View Filing |
| SC 13G | 2024-07-22 | 2024-07-22 | View Filing |
| SC 13D/A | 2024-07-02 | 2024-07-02 | View Filing |
| 4 | 2024-07-02 | 2024-07-02 | View Filing |
| SC 13G/A | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-06 | 2024-06-06 | View Filing |
| 4 | 2024-06-06 | 2024-06-06 | View Filing |
| 4 | 2024-06-06 | 2024-06-06 | View Filing |
| 4 | 2024-06-06 | 2024-06-06 | View Filing |
| 4 | 2024-06-06 | 2024-06-06 | View Filing |
| 4 | 2024-06-06 | 2024-06-06 | View Filing |
| 3 | 2024-06-06 | 2024-06-06 | View Filing |
| 8-K | 2024-06-06 | 2024-06-06 | View Filing |
| 8-K | 2024-05-20 | 2024-05-20 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 13.27% | 1.07 | 39 | 0.54 | 0.3 | 29.42 |
| Adaptive Wave | 10.56% | 1 | 1 | 1.47 | 1.01 | 3.48 |
| Heikin Ashi Strategy | 9.97% | 1.47 | 6 | 1.41 | 0.83 | 2.89 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |